论文部分内容阅读
目的探讨坎地沙坦对慢性心力衰竭伴阵发房颤患者P波最大时限(Pmax)及P波离散度(Pd)的影响。方法 51例慢性心力衰竭伴阵发性房颤患者被随机分为坎地沙坦治疗组(治疗组26例)和对照组(25例),慢性心力衰竭基本治疗两组相同,治疗组加用坎地沙坦2～4mg/d,在治疗前、治疗后6个月分别测量Pmax和Pmin,计算出Pd(Pd=Pmax-Pmin)。结果治疗前两组Pmax和Pd比较无显著差异(P>0.05);治疗6个月治疗组的Pmax、Pd显著降低,与对照组相比有显著意义(P<0.01);而对照组治疗前后相比没有差异(P>0.05)。治疗组房颤发作次数明显减少,与对照组比较差异有显著意义(P<0.01),结论坎地沙坦治疗慢性心力衰竭伴阵发性房颤患者可明显降低Pmax、Pd,减少房颤发作次数。
Objective To investigate the effect of candesartan on P max and P wave dispersion in patients with chronic heart failure and paroxysmal atrial fibrillation. Methods Fifty-one patients with chronic heart failure and paroxysmal atrial fibrillation were randomly divided into candesartan treatment group (26 cases) and control group (25 cases). The patients in chronic heart failure group were treated with the same basic treatment group and the treatment group Candesartan 2 ~ 4mg / d, before treatment, 6 months after treatment were measured Pmax and Pmin, calculated Pd (Pd = Pmax-Pmin). Results There was no significant difference in Pmax and Pd between the two groups before treatment (P> 0.05). Pmax and Pd in the treatment group for 6 months were significantly lower than those in the control group (P <0.01) There was no difference (P> 0.05). The incidence of atrial fibrillation in the treatment group decreased significantly compared with that in the control group (P <0.01). Conclusion Candesartan in patients with chronic heart failure and paroxysmal atrial fibrillation can significantly reduce Pmax, Pd, reduce the incidence of atrial fibrillation frequency.